Recombinant CD27 antibody

Catalog No. ABIN7072440

This anti-CD27 antibody is a Rabbit Chimeric antibody detecting CD27 in FACS, IP and Neut. Suitable for Mouse.

Quick Overview for Recombinant CD27 antibody (ABIN7072440)

Target: CD27 (CD27 Molecule (CD27))

Antibody Type: Recombinant Antibody

Reactivity: Mouse

Host: Rabbit

Clonality: Chimeric

Conjugate: This CD27 antibody is un-conjugated

Application: Flow Cytometry (FACS), Immunoprecipitation (IP), Neutralization (Neut)

Clone: RM27-3E5

Product Details anti-CD27 Antibody

Purpose: Anti-CD27 [RM27-3E5], Rabbit IgG, kappa

Specificity: This antibody is specific for the extracellular domain of murine CD27, a TNF-receptor superfamily member.

Characteristics:

Original Species of Ab: Rat

Original Format of Ab: IgG2a

Purification: Protein A affinity purified

Immunogen: This antibody was raised by immunising mouse with mouse CD27-human IgG1 Fc fusion protein. Isolated popliteal lymph node cells were then fused with P3U1 myeloma cells to produce stable hybridomas.

Isotype: IgG kappa

Application Details

Application Notes: This antibody recognises murine CD27, as confirmed by flow-cytometry and immunoprecipitation analysis (Sakanishi & Yagita, 2010), a member of the TNF-receptor superfamily. The interaction between CD27 and its ligand CD70, which is recognised by anti-CD70 antibody TAN 1-7 (Ab00816), is crucial to regulation of the survival and differentiation of T cells, B cells and NK cells. As a result, RM27-3E5 modulates multiple immune cell types. The original rat IgG2a version of RM27-3E5 did not deplete T cells, NKT or NK cells, but does enhance the proliferation of anti-CD3-stimulated splenic T cells (Sakanishi & Yagita, 2010). In murine models of melanoma, it promotes the persistence of tumour-specific CD8+ T cells within tumours, and reduces levels of PD-1 expression on CD8+ T cells (Roberts et al, 2010). Additionally, anti-CD27 reduces the proportion of FoxP3+ CD4+ T cells in tumours, and enhances the effector activity of IFNγ-secreting, tumour-infiltrating CD8+ T cells and NK cells (Roberts et al, 2010). Finally, anti-CD27 Ab treatment alters murine splenocyte cytokine production, significantly reducing IL-5 and IFN-γ synthesis, and increasing TNF-α production (Sumi et al, 2008). It also significantly suppresses total serum IgE levels, while significantly increasing IgG1 and IgG2a levels. These immune modulatory properties translate into potent anti-tumour effects in mice. Treatment of established murine melanoma with RM27-3E5 (rat IgG2a) resulted in a significant reduction in lung metastases and subcutaneous tumours, through an IFNγ-dependent mechanism mediated by CD8+ T cells and NK cells (Roberts et al, 2010). In murine models of T cell lymphoma, the tumour-specific CTL response induced by RM27-3E5 (rat IgG2a) promoted almost complete regression of tumours, regardless of CD27 expression on tumour cells (Sakanishi & Yagita, 2010). This antibody has been used to identify CD27-expressing cells through flow-cytometry (Koyanagi et al, 2012).

Comment:

This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2a format, for improved compatibility with existing reagents, assays and techniques.

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Target Details for CD27

Target: CD27 (CD27 Molecule (CD27))

Alternative Name: CD27

Background: TNFRS7, CD27 antigen, CD27L receptor, T-cell activation antigen CD27, Tumor necrosis factor receptor superfamily member 7

UniProt: P41272

Pathways: Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints